Enanta Pharmaceuticals, Inc., announced that a European Medicines Agency (EMA) panel has given a positive review to the use of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) plus Exviera (dasabuvir) without ribavirin (RBV) for the treatment of chronic ... Read more